Applying for the Innovatiekrediet: eligibility, required documentation, and capital stacking

Between laboratory feasibility and commercial revenue lies a funding gap notoriously difficult to bridge: the core technology remains unproven, cash flow is absent, and tangible collateral is non-existent. Commercial banks typically cannot structure facilities here. The Innovatiekrediet, administered by RVO, is designed precisely for this gap, serving as one of the most critical instruments in the funding mix for Brainport enterprises.

This article explains how the instrument operates, which projects succeed, what documentation must be submitted, and how to blend the scheme with complementary capital sources.

What the Innovatiekrediet entails

The Innovatiekrediet is a risk-bearing government loan designed to finance the development phase of challenging technical or clinical projects. The state co-funds a proportion of eligible R&D costs; the remaining portion must be provided via equity or matched through third-party financiers. Its standout feature is shared risk: should the project fail on clear technical grounds, the loan balance can be fully or partially written off subject to conditions. If the project succeeds commercially, the capital is repaid, typically carrying an interest rate reflective of the risk profile taken.

As such, the instrument occupies a middle ground between non-repayable grants and senior debt: significantly cheaper than external equity since it avoids equity dilution, yet subject to rigorous technical due diligence beyond standard lending. Eligibility terms, intervention rates, and funding budgets are reviewed periodically — verify current criteria directly via RVO before committing capital programmes.

Types of projects eligible for funding

What falls outside the scheme is equally vital: process optimisation lacking technical uncertainty, marketing and commercial roll-out expenses, and projects where technical performance is already established. A project whose risk is purely commercial in nature does not qualify.

• The project exhibits demonstrable technical or clinical development uncertainty — successful technical feasibility cannot yet be guaranteed
• Work is structured into a defined development programme with clear start and end milestones, rather than continuous operational R&D
• A validated commercial market case exists: target customers, price tolerance, and anticipated market demand are verified
• The business possesses the matched funding capacity to finance the non-subsidised share of development costs
• Projected revenues present a credible operational case for debt repayment upon successful development

Required documentation for submission

Evaluation centres on three pillars: technology, commercial market potential, and financial resilience of the business throughout the development timeline. A proposal proving deficient in any one of these pillars will fail, regardless of how compelling the other two may be.

• A detailed technical project plan with clear work packages, defined deliverables, and objective disclosure of technical risks
• A formal state-of-the-art appraisal: what existing technology is commercially available, and why your solution advances beyond it
• A commercial market analysis identifying specific customers, pricing structures, and volume forecasts — ideally backed by letters of intent or pilot agreements
• A line-item project budget spanning internal hours, consumables, subcontracted R&D, and equipment, accompanied by a fully committed matched-funding structure
• A multi-year cash flow forecast mapping corporate liquidity across the entire development lifespan
• An intellectual property strategy detailing protection mechanisms, ownership structure, and formal freedom-to-operate assessments

The cash flow projection is the most commonly underestimated element. A technically brilliant project that runs out of operational working capital halfway through development cannot be funded. Refer also to our guide on building a cash flow forecast.

Stacking alongside alternative funding sources

The Innovatiekrediet is rarely a standalone solution. In practice, businesses deploy a blended funding structure: WBSO reduces payroll taxes on eligible R&D hours to improve month-on-month cash flow; the Innovatiekrediet funds direct technical project costs; equity or angel investors provide the matched co-financing share; and as soon as commercial manufacturing begins, asset finance and working capital facilities support scale-up.

Pay careful attention to sequencing and eligibility rules. Certain public schemes prohibit double-dipping on identical eligible costs, whereas others are structured to complement each other. Establish your financial architecture prior to submitting formal applications, as redistributing cost heads between schemes retrospectively is complex and creates administrative delays. See also stacking grants and debt capital.

Processing times and project scheduling

For a thoroughly prepared application, plan for a timeline of several months from the initial intake meeting through to the formal decree, including formal technical clarification rounds. Do not initiate development prior to approval: capital expenditure incurred before official application submission is generally deemed ineligible.

Practically, this means structuring the application concurrently with the final research phase, while ensuring your corporate business plan accounts for a window where project activities wait but operational overheads continue.

Why this aligns well with the Brainport ecosystem

The Eindhoven region houses a dense concentration of businesses falling squarely into the qualifying profile: advanced high-tech suppliers developing proprietary products alongside contract manufacturing, spin-offs commercialising proven lab physics into manufacturable systems, and medtech innovators undergoing clinical development. For these firms, the default funding route is often venture capital, diluting founder equity when company valuations are at their lowest.

Here, a risk-bearing loan provides genuine strategic value: funding the high-risk technical development phase without surrendering substantial equity at the point of lowest corporate valuation.

Next steps

• Screen your project for technical risk, discrete project boundaries, and commercial feasibility before investing time into an application
• Map which funding schemes apply to which expenditure items, confirming where double-funding restrictions apply
• Draft a continuous cash flow projection covering the entire project timeline, including the formal review period
• Compile tangible market validation: expressions of interest, pilot partnership agreements, letters of intent
• Subject your funding application to independent review before submission — a rejected file primarily results in costly time lost

Frequently asked questions

What exactly is the Innovatiekrediet?

A risk-bearing government loan designed to fund the development phase of technically or clinically challenging projects. If the project succeeds, the loan is repaid with interest; if it fails on proven technical grounds, the liability can be written off subject to conditions.

Can I combine the Innovatiekrediet with WBSO?

Stacking both schemes is common practice, but they cannot claim against the exact same cost items. Establish the allocation of eligible expenditure across both programmes prior to submission.

How long does the application process take?

Expect a timeline of several months between the initial intake meeting and the final award decree, including formal assessment rounds. Expenditure incurred prior to formal submission is normally ineligible.